Research Use
Also known as ACTH(4-10) analog

Get a source-linked, educational explanation from this profile.

Complete Research Guide

Open each section for the available evidence. Gaps are stated rather than inferred.

Overview

Semax is listed as nootropic / neuroprotective.

  • •Cognitive enhancement
  • •Stroke recovery
  • •Neuroprotection
  • •ADHD (off-label)

Regulatory status: Approved in Russia; not FDA-approved.

Structure & Properties

Compound: Semax; also known as ACTH(4-10) analog.

Pharmacologic class: Nootropic / Neuroprotective.

Known delivery routes: Intranasal.

Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.

How It Works

ACTH analog — increases BDNF, NGF, and VEGF expression; enhances dopaminergic/serotonergic tone; neuroprotective via anti-apoptotic mechanisms.

  • •Improved memory and focus
  • •Stroke recovery support
  • •Mood modulation
Human Research

Evidence grade: Pre-clinical / Observational

Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.

Laboratory Research

Russian approved drug; limited Western peer review

Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.

Processing & Interactions

Timing and exposure

Intranasal, 1–2× daily in the morning or before focus-heavy tasks. Avoid late-evening dosing — may impair sleep in sensitive users.

Potential interactions and combinations to avoid

  • •Stimulants (high-dose caffeine, amphetamines) — additive dopaminergic load

Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.

Safety & Precautions

Known or reported risks

  • •Mild hypertension
  • •Limited Western long-term data

Contraindications

  • •Uncontrolled hypertension
  • •Pregnancy
  • •Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
  • •Bipolar disorder, psychosis, or active mania
  • •Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
  • •Recent intracranial haemorrhage or unstable neurologic injury
  • •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
  • •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
  • •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
  • •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
  • •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
  • •Children and adolescents with open growth plates (unless under specialist endocrine care)
  • •Active or recently treated malignancy without oncology clearance
  • •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision

Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.

Administration & Studied Formulations

Reference range: 300–900 mcg/day

Frequency: Once or twice daily

Cycling: 2–4 weeks on / 2 weeks off.

Intranasal

Standard — 0.1% or 1% solution.

Nasal spray or dropper. 2–3 drops per nostril AM, optionally midday. Avoid evenings.

Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.

Applications & Related Therapies

Potentially complementary measures

  • •Selank for anxiolytic balance
  • •Cerebrolysin for neuro-recovery

Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.

Cases, Considerations & Ethics

Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.

Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.

Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.

What is Semax?

In plain words

Semax is a lab-made chain of seven amino acids, the building blocks of proteins. Studies suggest it may change signals that help brain cells survive and communicate. Researchers study it for memory and thinking skills and for recovery after stroke. Strong human evidence and long-term safety data are limited, and mild increases in blood pressure have been reported.

Technical definition

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4–10) fragment and studied for nootropic and neuroprotective effects. Its molecular receptor target is not firmly established; preclinical findings suggest modulation of BDNF, NGF, and VEGF expression, dopamine and serotonin signaling, and pathways that reduce programmed cell death. Semax is approved in Russia but is not FDA-approved; evidence for cognitive enhancement and stroke recovery remains largely preclinical or observational.

Function

Primary
Cognitive enhancement · Stroke recovery
Secondary
Neuroprotection · ADHD (off-label)
Mechanism
ACTH analog — increases BDNF, NGF, and VEGF expression; enhances dopaminergic/serotonergic tone; neuroprotective via anti-apoptotic mechanisms.
Evidence
Pre-clinical / Observational
Research
Russian approved drug; limited Western peer review

Dosing

Range
300–900 mcg/day
Frequency
Once or twice daily
Route
Intranasal

Recommended Time of Day

Morning — intranasal; avoid evening use as it can be mildly stimulating.

See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.

Administration & Technique

Intranasal
Standard — 0.1% or 1% solution.
DeviceNasal spray or dropper.
Technique2–3 drops per nostril AM, optionally midday. Avoid evenings.

Injection & Application Sites

Front
Back
Intranasal
  • Intranasal — Alternate nostrils, spray on inhalation, do not sniff hard.

Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.

Cycling

2–4 weeks on / 2 weeks off.

Timing & Interactions

When to take
Intranasal, 1–2× daily in the morning or before focus-heavy tasks. Avoid late-evening dosing — may impair sleep in sensitive users.
Do not combine with
  • ·Stimulants (high-dose caffeine, amphetamines) — additive dopaminergic load
Complements
  • ·Selank for anxiolytic balance
  • ·Cerebrolysin for neuro-recovery

Storage & Reconstitution

Powder (Pre-Reconstitution)
Lyophilized powder: refrigerate 2–8°C for up to 24 months, or freeze at –20°C for extended storage. Keep sealed, desiccated, and protected from light.
After Reconstitution
After reconstitution with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Discard if cloudy, discolored, or precipitated.
Notes
Do not freeze after reconstitution — freeze/thaw cycles degrade most peptides.
Full BAC water & reconstitution guide →How to read a COA →

Reconstitution Calculator

Concentration
2.50 mg/mL
Volume per dose
0.100 mL
Insulin syringe
10.0 units (U-100)

1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.

Your Notes

Your Notes

Sign in to save personal notes on Semax and sync them to Vial Lab.

Benefits

  • ·Improved memory and focus
  • ·Stroke recovery support
  • ·Mood modulation

Risks

  • ·Mild hypertension
  • ·Limited Western long-term data

Contraindications

  • ·Uncontrolled hypertension
  • ·Pregnancy
  • ·Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
  • ·Bipolar disorder, psychosis, or active mania
  • ·Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
  • ·Recent intracranial haemorrhage or unstable neurologic injury
  • ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
  • ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
  • ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
  • ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
  • ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
  • ·Children and adolescents with open growth plates (unless under specialist endocrine care)
  • ·Active or recently treated malignancy without oncology clearance
  • ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision

Regulatory

Approved in Russia; not FDA-approved

Veterinary Use (Pets)

No established veterinary protocol for Semax. Consult a licensed veterinarian before considering off-label use in any species.

Full veterinary reference →
Sign in to save favorites & stacks

Educational reference only. Not medical advice. Consult a qualified clinician before starting any peptide protocol.

Non-FDA-approved peptides are for research use only. Not for human or animal consumption.